...
首页> 外文期刊>Probiotics and Antimicrobial Proteins >Partial Purification and Characterization of a Bacteriocin DT24 Produced by Probiotic Vaginal Lactobacillus brevis DT24 and Determination of its Anti-Uropathogenic Escherichia coli Potential
【24h】

Partial Purification and Characterization of a Bacteriocin DT24 Produced by Probiotic Vaginal Lactobacillus brevis DT24 and Determination of its Anti-Uropathogenic Escherichia coli Potential

机译:益生菌短乳杆菌DT24产生的细菌DT24的部分纯化,鉴定及其抗尿毒症性大肠杆菌的测定

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The emergence of antibiotic resistance has increased the interest for finding new antimicrobials in the past decade. Probiotic Lactic acid bacteria producing antimicrobial proteins like bacteriocin can be excellent agents for development as novel therapeutic agents and complement to conventional antibiotic therapy. Uropathogenic Escherichia coli, most causative agent of Urinary tract infection, has developed resistance to various antibiotics. In the present investigation, antibacterial substance likebacteriocin (Bacteriocin DT24) produced by probiotic Lactobacillus brevis DT24 from vaginal sample of healthy Indian woman was partially purified and characterized. It was efficiently working against various pathogens, that is, Uropathogenic E. coli, Enterococcus faecium, Enterococcus faecalis and Staphylococcus aureus. The antimicrobial peptide was relatively heat resistant and also active over a broad range of pH 2–10. It has been partially purified by ammonium sulfate precipitation and gel filtration chromatography and checked on reverse-phase high-performance liquid chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of bacteriocin DT24 was approximately 7-kDa protein. The peptide is inactivated by proteolytic enzymes, trypsin and lipase but not when treated with catalase, alpha-amylase and pepsin. It showed bacteriostatic mode of action against uropathogenic E. coli. Such characteristics indicate that this bacteriocin-producing probiotic may be a potential candidate for alternative agents to control urinary tract infections and other pathogens.
机译:在过去的十年中,抗生素耐药性的出现增加了寻找新的抗菌素的兴趣。产生抗菌蛋白(如细菌素)的益生菌乳酸菌可以作为新型治疗剂发展成为极好的药物,并且可以补充常规抗生素治疗。泌尿道致病性大肠杆菌是泌尿道感染的最病原体,已对多种抗生素产生耐药性。在本研究中,益生菌短乳杆菌DT24从健康的印度妇女的阴道样本中产生的抗菌物质(如细菌素)(细菌素DT24)被部分纯化和表征。它有效地对抗各种病原体,如致病性大肠杆菌,粪肠球菌,粪肠球菌和金黄色葡萄球菌。抗菌肽相对耐热,并且在2-10的广泛pH范围内也具有活性。它已通过硫酸铵沉淀和凝胶过滤色谱法进行了部分纯化,并通过反相高效液相色谱进行了检查。细菌素DT24的十二烷基硫酸钠-聚丙烯酰胺凝胶电泳约为7-kDa蛋白。该肽可通过蛋白水解酶,胰蛋白酶和脂肪酶失活,但在用过氧化氢酶,α-淀粉酶和胃蛋白酶处理时不会失活。它显示了对尿路致病性大肠杆菌的抑菌作用。这些特征表明,这种产生细菌素的益生菌可能是控制尿路感染和其他病原体的替代药物的潜在候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号